Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis - 30/06/22
, Seokyung An, BS c, Alyssa A. Grimshaw, MSLIS d, Jennifer Frampton, DO, MPH e, E Magnus Ohman, MBBS f, Sunil V. Rao, MD f, Michael G. Nanna, MD, MHS e, ⁎Abstract |
Introduction |
The decision to shorten the duration of DAPT following PCI in patients with ACS remains controversial because of the concern for increased ischemic events.
Methods |
We performed a comprehensive literature search in seven databases to explore the efficacy of 1 to 3 months of DAPT in patients who underwent PCI for ACS. Randomized controlled trials that compared 1 to 3 months with 6 to 12 months of DAPT after PCI for ACS were identified. Integrated hazard ratio (HR) and 95% confidence interval (CI) were calculated by random effects model for each prespecified outcome of interest. Meta-regression analyses were performed to examine the association of outcomes with select patient characteristics.
Results |
A total of 9 randomized controlled trials consisting of 25,907 patients were included. There was no difference in the hazard of NACE (HR 0.92, 95% CI 0.79-1.07) and MACE (HR 0.96, 95% CI 0.78-1.17) between 1 and 3 months of DAPT and 6 to 12 months of DAPT. However, implementing 1 to 3 months of DAPT was associated with lower hazard of both any bleeding (HR 0.55, 95% CI 0.46-0.66) and major bleeding (HR 0.47, 95% CI 0.36-0.62). Meta-regression revealed a nonsignificant but increasing trend of both NACE and MACE with greater proportion of left main and left anterior descending coronary artery lesions and greater proportion of STEMI included in the trials.
Conclusion |
Our findings suggest that 1 to 3 months of DAPT has similar efficacy for preventing ischemic events with reduced bleeding risk compared with 6 to 12 months of DAPT.
Le texte complet de cet article est disponible en PDF.Abbreviations : ACS, CI, CV, DAPT, DES, HR, LAD, LM, MACE, MI, NSTEMI, PCI, RCT, STEMI
Plan
Vol 251
P. 101-114 - septembre 2022 Retour au numéro
Article précédent
- Longer term benefits of exercise and escitalopram in the treatment of anxiety in patients with coronary heart disease: Six month follow-up of the UNWIND randomized clinical trial
- James A. Blumenthal, Patrick J. Smith, Wei Jiang, Alan Hinderliter, Lana L. Watkins, Benson M. Hoffman, William E. Kraus, Stephanie Mabe, Lawrence Liao, Jonathan Davidson, Andrew Sherwood
- Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial
- Jacob B. Pierce, Robert J. Mentz, Jie-Lena Sun, Brooke Alhanti, David J. Whellan, William E. Kraus, Ileana L. Piña, Mona Fiuzat, Christopher M. O'Connor, Stephen J. Greene
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?